“Demand for MCC continues to grow rapidly in Asia,” said Michael Wilson, president of FMC’s Specialty Chemicals Group. “This addition of significant new capacity to our MCC network will be needed to supply high-quality products and service to our Asian customers while at the same time providing us with greater flexibility to support global growth with our existing capacity in North America and Europe.”
FMC Biopolymer, a business division of Philadelphia-based FMC Corp., already manufactures food and pharmaceutical grade MCC at plants in Cork, Ireland, and Newark, Del.
The Thailand facility initially will manufacture Avicel colloidal MCC. Its design will allow for future volume expansions and the manufacture of different product lines for both the food and pharmaceutical markets.
“Today’s announcement represents another major step in FMC’s Vision 2015 growth strategy,” said Pierre Brondeau, president, chief executive officer and chairman of FMC Corp., on July 24. “This significant investment underscores FMC’s continuing commitment to profitably grow our signature product lines and to introduce or broaden the availability of leading FMC technologies in rapidly growing regions.”
